This is a preview of subscription content, log in via an institution to check access.
Reference
Rivolo S, et al. Comparison of Safety Management Costs Across Chimeric Antigen Receptor (Car) T Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma. 25th Congress of the European Haematology Association : abstr. EP1752, 11 Jun 2020. Available from: URL: http://link.adisinsight.com/d8FSr
Rights and permissions
About this article
Cite this article
AE costs lower with liso-cel than with axi-cel or tisagenlecleucel. PharmacoEcon Outcomes News 858, 1 (2020). https://doi.org/10.1007/s40274-020-6974-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6974-3